Specialist medtech company Angle announced plans to raise funds via a firm placing of new ordinary shares with existing institutional investors as well as three new major institutional investors. The fundraising will facilitate the commercialisation of its patented Parsortix liquid biopsy system which has the potential to transform the diagnosis and treatment of cancer by making it possible to harvest intact cancer cells from patient blood for analysis.    

Cenkos acted as nominated adviser, agent and broker, and WG Partners acted as broking agent to Surrey-based Angle.

Hill Dickinson corporate partners Ian Gillis and Jonathan Gillow advised Cenkos and WG Partners on the transaction.

Ian commented: “We’re delighted to once again assist Cenkos and WG Partners. This is the latest in a number of transactions our capital markets team has advised on in 2016. The team continue to regularly advise companies, investment banks and corporate advisers on ISDX, AIM and Main Market transactions.”